Masako Kato

Dr. Masako Kato

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2026 in Cancers
Verified
Journal Article
Open access
PDF file
RORyotaro Ohkuma
Ryotaro Ohkuma
TITomoyuki Ishiguro
Tomoyuki Ishiguro
HAHirotsugu Ariizumi
Hirotsugu Ariizumi
MSMasahiro Shimokawa
Masahiro Shimokawa
GIGo Ikeda
Go Ikeda
HAHoriike Atsushi
Horiike Atsushi
Background/Objectives: Evidence regarding associations between local therapy before an indexed systemic regimen and subsequent outcomes in advanced soft tissue sarcoma (STS) remains limited. We evaluated outcomes within four regimen-defined cohorts and explored associations with prior local-therapy history. Methods: This retrospective cohort included 75 patients with recurrent or metastatic STS who contributed 155 treatment episodes: doxorubicin (n = 44), trabectedin (n = 31), pazopanib (n = 42), and eribulin (n = 38). Progression-free survival (PFS) and overall survival (OS) were measured from initiation of the indexed regimen. Surgery, local ablative therapy, and radiation therapy were assessed separately and in combined categories. Post hoc analyses were restricted to leiomyosarcoma. Results: Median PFS was 3.4, 3.1, 5.1, and 3.9 months, respectively. PFS was longer with any local therapy and surgery and/or ablation in the trabectedin cohort (p = 0.0342 and p = 0.0111) and with surgery and/or ablation in the eribulin cohort (p = 0.0352). Longer indexed-regimen OS was observed in surgery-containing categories in the doxorubicin and eribulin cohorts. In selected multivariable models, local therapy was associated with OS in doxorubicin- and eribulin-treated episodes and with PFS in eribulin-treated episodes. Leiomyosarcoma-restricted analyses did not consistently reproduce the full-cohort findings. Conclusions: Prior local-therapy history was associated with PFS or OS in selected within-cohort analyses. The associations may reflect local-treatment effects, differences among selected patients, or both; however, the study cannot distinguish these contributions. No between-regimen differences were formally tested. These findings support individualized multidisciplinary assessment and external validation.

11 October 2025 in Current Oncology
Verified
Journal Article
Open access
PDF file
SKShota Kikuchi
Shota Kikuchi
TFTakashi Fukagai
Takashi Fukagai
JYJin Yamatoya
Jin Yamatoya
KOKazuhiko Oshinomi
Kazuhiko Oshinomi
MNMasakazu Nagata
Masakazu Nagata
YIYoshinori Ito
Yoshinori Ito
Radioactive seed migration after low-dose-rate brachytherapy (LDR-BT) for prostate cancer is a known phenomenon; however, its clinical impact remains unclear. We retrospectively analyzed 611 patients treated with LDR-BT using loose iodine-125 seeds. Post-treatment imaging was used to assess seed migration. Treatment efficacy was evaluated using post-plan dosimetry (V100 and D90) and biochemical recurrence-free survival (bRFS). Seed migration was observed in 150 patients (24.5%) within 1–3 months post-treatment, involving a total of 210 seeds. Migration sites included lungs, vasculature, and seminal vesicles. Hematogenous migration was significantly associated with higher seed counts. Seminal vesicle migration was linked to increased needle usage and absence of neoadjuvant hormone therapy. No significant differences were observed in V100, D90, or bRFS between patients with or without seed migration. However, migration of ≥3 seeds correlated with significantly lower V100 and with a trend toward decreased bRFS. Limited seed migration appears to have minimal clinical impact. However, ≥3 migrated seeds may reduce dosimetric quality and affect treatment efficacy. Risk factors include larger prostate volume as well as higher seed and needle counts. Improved planning and using linked seeds may reduce migration and improve outcomes in LDR-BT for prostate cancer.

1 July 2024 in European Journal of Breast Health
Verified
Journal Article
Open access
AAArisa Ata-Shiroshita
Arisa Ata-Shiroshita
TKTakashi Kuwayama
Takashi Kuwayama
MKMasako Kato
Masako Kato
HSHidenori Shinjo
Hidenori Shinjo
KMKazunori Miyaura
Kazunori Miyaura
Seigo NakamuraSeigo Nakamura
Seigo Nakamura
Retrospective Analysis of the Clinical Usefulness of a Strut-Adjusted Volume Implant in a Single Center - European Journal of Breast Health